DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge

Modified vaccinia Ankara (MVA) is being tested in humans as an alternative to the current smallpox vaccine Dryvax. Here, we compare the magnitude and longevity of protective immune responses elicited by a DNA/MVA HIV-1 vaccine with those elicited by Dryvax using a monkeypox virus/macaque model. The...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nigam, Pragati, Earl, Patricia L., Americo, Jeffrey L., Sharma, Sunita, Wyatt, Linda S., Edghill-Spano, Yvette, Chennareddi, Lakshmi S., Silvera, Peter, Moss, Bernard, Robinson, Harriet L., Amara, Rama Rao
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Inc. 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2072046/
https://ncbi.nlm.nih.gov/pubmed/17507071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.virol.2007.04.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados